1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Axitinib (Renal Cell Carcinoma) – Analysis and Forecasts to 2020

The report provides detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020).

 
PRLog - Nov. 16, 2011 - “Axitinib (Renal Cell Carcinoma)- Analysis and Forecasts to 2020” provides Axitinib sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. The report is supported by a comprehensive patient based model which provides detailed information on key inputs including prevalence rates, market penetration, annual cost of therapy.

For Sample Pages, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?...

Scope of the report:
Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
Analysis and review of Axitinib including historical sales data
Qualitative and quantitative assessment of market space
Analysis of the trends, drivers and restraints shaping and defining the markets
In-depth analysis of Axitinib including efficacy, safety, pricing, competition and other details which influence its sales potential
Detailed sales forecast for 2012-2020 for Axitinib in each of the seven major markets

Why you need this report:
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of competition by understanding the changing competitive landscape
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
Examine the historical sales performance of a drug in seven major markets
Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Interactive computing model enables you to input your own assumptions such as market penetration and annual cost of therapy to arrive at your own estimates.

Do follow us at facebook:
http://www.facebook.com/PharmaceuticalsandHealthcareMarke...
Visit our report store: http://www.globalmarketsdirect.com

For more details contact:
pressreleases@globalmarketsdirect.com
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

--- End ---

Click to Share

Contact Email:
***@globalmarketsdirect.com
Source:rgunnam
Phone:+914066166782
Zip:EC4Y 0AN
State/Province:London - United Kingdom
Industry:Health
Tags:Renal Cell Carcinoma, Axitinib, pharmaceuticals_and_healthcare
Shortcut:prlog.org/11725427
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share